Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
Moelis & Company (MC) just gave investors a clean entry after a sharp sell-off. The advisory firm still prints high ROE, solid free cash flow and a dividend yield that cushions downside. Technical momentum and falling short interest add to the bull case. Here's a pragmatic trade plan with entry, stop and targets across three horizons.
<p>PDD Holdings (PDD) trades at $83.81 with a market cap of roughly $119.3B and a forward P/E under 9. The stock has been punished after a sharp deceleration in revenue growth and margin compression, but underlying cash generation and a low bar for future results create a tactical long opportunity. This is a risk-defined trade: entry $84.00, stop $…
Netflix plunged after cautious guidance, but the company's record quarterly revenue ($12.56B), strong free cash flow ($11.89B), and attractive risk/reward amid technical oversold conditions argue for a tactical long. This trade plan targets a mid-term rebound over the next 45 trading days while managing downside risk with a strict stop.
VINCI (VCISY) ADR is trading near $33.79 after recent weakness. The stock's fundamentals - a diversified concessions/construction profile, a 2.8% yield, buyback activity and recent contract awards - support a mid-term tactical long. Entry $33.70, target $40.00, stop $31.50; horizon mid term (45 trading days).
monday.com plunged through 2026 amid AI-driven fear and headline selling. The business continues to grow 24% YoY, just reported $351M in revenue and positive operating cash flow, and now trades at a fraction of prior multiples. I’m putting a clear trade on: long MNDY at current levels with a $140 target and $69 stop — a high-conviction, high-risk a…
Oracle is trading near $125 with a valuation that appears reasonable versus earnings and cash-flow multiples. Strong cloud momentum and large remaining performance obligations underpin upside, but negative free cash flow, heavy leverage and concentrated exposure to OpenAI create a credible path to further downside. This trade idea is a tactical mid…
Gevo looks positioned to convert recent non-dilutive cash events and improving operating leverage into a step-change in EBITDA. With a market cap near $386M and enterprise value of $475M, shares are pricing in slow progress; proof points from tax-credit monetization, carbon credit sales and a favorable SAF market could re-rate the stock. This is a …
GE Aerospace's shares have pulled back from their June highs, but fundamentals - strong aftermarket services, a hefty installed base, and $7.46B of free cash flow - support upside. Valuation is rich on headline multiples but defensible given returns and cash generation. This trade targets $385 with a disciplined $320 stop on a long-term (180 tradin…
Nano Labs (NA) trades at $1.76 with a market cap of roughly $40.9M, a trailing P/E near 2.1 and a P/B of 0.43. Recent MoU aimed at North America AI data centers, a product launch and insider buying give the stock a case for mean reversion. Low liquidity, a non-binding partnership structure and cyclical semiconductor exposure keep risk high. This is…
Arch Capital (ACGL) looks attractively cheap on headline multiples, but the market is starting to price flatter reinsurance renewals. With shares near $100 and momentum losing steam, we prefer a tactical short into mid-term weakness: enter at $100.03, target $88.00, stop $106.00. This is a mid-term (45 trading days) trade sized for investors who ac…
Q32 Bio's recent program developments and corporate actions have shifted the risk profile from pure early-stage binary to one with tangible commercial optionality and cash support. I outline a mid-term trade plan that captures upside to program re-rating while limiting downside with a defined stop.
Ecolab is a durable, cash-generative leader in water, hygiene and thermal-management services. Recent results show low-single-digit organic growth, solid margin expansion and healthy free cash flow. The $4.75B CoolIT acquisition gives Ecolab direct exposure to the fast-growing AI data-center cooling market, adding near-term revenue and long-term op…
Grindr is showing durable paid-user strength and profitable growth that the market is under-appreciating. With revenue up ~28% y/y to $440M in 2025 and net income returning to $95M, the stock at $15.76 is offering asymmetric upside toward $20 while still managing meaningful downside risk from leverage and governance noise. We upgrade the rating and…
FedEx's freight unit sits with spare capacity while overall freight demand shows signs of recovery. At $318, the stock trades at ~17x earnings with solid free cash flow and room for margin recovery if pricing normalizes. This trade targets a re-test of the $345 area over the next 45 trading days with a disciplined stop below $298.
Headlines and volatile sector sentiment have amplified the bear case on Webull. We believe the market is over-discounting monetization upside and franchise value. This trade lays out a disciplined long with entry, stop, and target, and a clear catalyst checklist to re-rate the stock.
POSCO Holdings (PKX) looks like a tactical long after recent investor-event takeaways that reinforced the company’s pivot into EV battery materials and steady steel sales. Fundamentals and technicals support a mid-term rebound toward the $60s while valuation is reasonable given a low PB and a 2.7% yield. Trade plan: enter at $51.22, stop at $47.00,…
Inhibrx is transitioning from clinical-stage story to commercial-stage execution with a recently launched rare-disease asset and a high-value oncology program approaching a Phase 2 readout. The market currently prices the company like a binary, high-volatility biotech. I favor a structured long: buy on weakness, trim into rallies, and hold through …
Annaly (NLY) just looks cheaper and more resilient than I allowed for earlier. A visible shift in portfolio mix toward higher-yielding residential credit and mortgage servicing rights, plus a raised quarterly dividend of $0.75, means Q2 should validate improving earnings power. At $23.50 entry, this is a pragmatic swing trade: buy on the mix story …
The Western Union Company (WU) trades at roughly $8.33, sporting an ~11% dividend yield and a trailing P/E near 6x. Cheap multiples, solid free cash flow of $377.7M, and a pending Intermex acquisition that is almost fully approved create an asymmetric risk/reward for patient income-value buyers. The trade is to buy into the turnaround with a clear …
Bladex (BLX) has defensive fundamentals, a reliable dividend and recent credit improvement. At $59.95 shares trade at ~10x earnings and 1.5x book while yielding ~4.4%. Combine an apparent BBB+ upgrade, steady payout history and technical support near the 10-day SMA, and you get a tactical long with asymmetric upside. This trade lays out an entry at…
FEMSA (FMX) looks attracive for a mid-term long trade. The company combines defensive beverage cash flows with a fast-growing proximity retail footprint and steady dividend income. Valuation is reasonable for a diversified consumer platform - market cap $26.1B - with a 52-week range of $83.08 to $134.52. Key near-term catalysts include ownership co…
Nexa Resources (NEXA) looks like a mispriced play on base metals exposure. With a market cap of roughly $1.66B, a P/E under 9 and a dividend coming into focus, the stock appears to have upside that the market has not fully baked in. This trade idea lays out entry, stop and target levels across defined horizons and highlights the operational and mac…
Red Rock Resorts (RRR) sits above its near-term moving averages with healthy cash flow and a modest dividend. With a market cap near $7.0B and an enterprise value around $7.38B, the case for a mid-term long is built on continued Las Vegas demand, development projects and scarce developable land near core resorts. Trade plan: enter $66.75, target $6…
Monopar (MNPR) is a small-cap biotech with a lead late-stage asset for Wilson disease, ALXN1840. Positive Phase 3 signals, supportive Phase 2 histology and neurologic readouts, and an NDA on track for mid-2026 create a near-term regulatory catalyst. With market cap ~$729M versus reported cash runway through 2027, the stock is positioned for a mater…
F.N.B. Corp. reported continued steady performance, raised its quarterly dividend to $0.13, and authorized a $250 million buyback. The stock trades near its 52-week high on attractive multiples (PE ~12, PB ~1.02) and generates solid free cash flow. We outline an actionable long trade with entry, stop and target, plus the key catalysts and risks to …
